Patents by Inventor Michael R. Lerner

Michael R. Lerner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7829298
    Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: November 9, 2010
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: David J. Unett, Ruoping Chen, Jeremy G. Richman, Daniel T. Connolly, Huong T. Dang, Bryan J. Choi, James N. Leonard, Yaron Hakak, Chen W. Liaw, Dominic P. Behan, Derek T. Chalmers, Michael R. Lerner, Kevin P. Lowitz
  • Patent number: 6602856
    Abstract: Peptide antagonists of &agr;-melanocyte stimulating hormone are disclosed, together with methods of inhibiting the effects of &agr;-melanocyte stimulating hormone on cells or tissues sensitive to that hormone. In particular, methods for lightening the pigmentation of skin and for treating malignant melanoma, as well as kits for practicing the invention are also disclosed.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: August 5, 2003
    Inventors: J. Mark Quillan, Channa K. Jayawickreme, Michael R. Lerner
  • Publication number: 20030008331
    Abstract: The invention exploits the evolutionary principles responsible for the development of the broad spectrum general odorant detector system, to create a G-protein coupled receptor (GPCR) based system capable of detecting and discriminating between thousands of chemicals. The means is to subject a defined set of receptors such as G-protein coupled receptors, tyrosine kinase receptors, and/or ion channels, to the types of evolutionary forces that have created the array of approximately 1,000 natural receptors used in general olfaction by higher animals. This goal is accomplished by ‘directed evolution-in-a-test-tube’ by imposing very high rates of mutation and extremely strict selection criteria to create a sensor. The novel sensor is selected using a sensitive melanophore-based functional bioassay. Stimulation of the sensor upon interaction with chemical signatures derived from ordinances will result in a calcium ion flux rapidly detectable as a fluorescent signal.
    Type: Application
    Filed: August 28, 2002
    Publication date: January 9, 2003
    Inventor: Michael R. Lerner
  • Patent number: 6475733
    Abstract: The invention exploits the evolutionary principles responsible for the development of the broad spectrum general odorant detector system, to create a cell-surface receptor based system capable of detecting and discriminating between thousands of chemicals. This is accomplished by subjecting a defined set of cell-surface receptors such as G-protein coupled receptors, tyrosine kinase receptors, and/or ion channels, to the types of evolutionary forces that have created the array of approximately 1,000 natural receptors used in general olfaction by higher animals. This goal is further accomplished by a ‘directed evolution-in-a-test-tube’ method, imposing very high rates of mutation and extremely strict selection criteria to create a sensor. The novel sensor of the present invention is selected using a sensitive melanophore-based functional bioassay.
    Type: Grant
    Filed: October 4, 2000
    Date of Patent: November 5, 2002
    Assignee: Lerner Pharmaceuticals, Inc.
    Inventor: Michael R. Lerner
  • Patent number: 6051386
    Abstract: A method for identifying a chemical that acts as an agonist for a G-protein coupled cell surface (GPC) receptor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 18, 2000
    Assignee: Bunsen Rush Laboratories, Inc.
    Inventors: Michael R. Lerner, Ethan A. Lerner
  • Patent number: 5601992
    Abstract: A method for detecting the interaction between an oligomeric molecule and a target is provided. A plurality of beads is applied to a substrate, each bead having associated therewith multiple copies of only a single oligomeric molecule. The beads are substantially spaced-apart from one another and are substantially immobilized on the substrate. Conditions are applied such that a substantial portion of the multiple copies associated with each bead can disassociate from and diffuse into the substrate, the substrate constructed and arranged to permit only substantially localized diffusion. A localized signal occurring as a result of the diffusion is detected. Coated beads and libraries of coated beads also are provided.
    Type: Grant
    Filed: September 9, 1994
    Date of Patent: February 11, 1997
    Assignee: Bunsen Rush Laboratories, Inc.
    Inventors: Michael R. Lerner, Channa K. Jayawickreme, Ethan A. Lerner
  • Patent number: 5462856
    Abstract: A method for identifying a chemical that acts as an agonist for a G-protein coupled cell surface (GPC) receptor.
    Type: Grant
    Filed: July 16, 1991
    Date of Patent: October 31, 1995
    Assignee: Bunsen Rush laboratories, Inc.
    Inventors: Michael R. Lerner, Ethan A. Lerner
  • Patent number: 5300097
    Abstract: Disclosed is a therapeutic device including an optical source including means for generating ultraviolet (UV) radiation, and a light delivery apparatus. The light delivery apparatus includes a body member and a plurality of optical fibers extending therefrom. Each of the optical fibers includes a proximal tip affixed to the body member, a distal tip at the end of the fiber opposite the proximal tip, and means for coupling the generated radiation from the proximal tips of the fibers through the fibers, and to the distal tips. The distal tips are characterized by a radius of curvature in the range 0.25 to 2.0 mm. The coupling means includes a flexible central core disposed within a flexible outer cladding. The central core has a diameter in the range of 0.1 mm to 1.0 mm, and the cladding has a refraction less than the index of refraction of the core.
    Type: Grant
    Filed: September 18, 1992
    Date of Patent: April 5, 1994
    Inventors: Ethan A. Lerner, R. Rox Anderson, Michael R. Lerner
  • Patent number: 5294543
    Abstract: Purified DNA comprising a sequence encoding chrysoptin.Chrysoptin can be used to alter the hemodynamic or hemostatic properties of an animal's blood by administering to the animal an effective amount of chrysoptin.
    Type: Grant
    Filed: April 8, 1992
    Date of Patent: March 15, 1994
    Assignee: The General Hospital Corporation
    Inventors: Ethan A. Lerner, Michael R. Lerner
  • Patent number: 4564597
    Abstract: Anti-Sm antibodies are produced by the hybridoma technique and employed to test for lupus erythematosus in humans.
    Type: Grant
    Filed: March 18, 1981
    Date of Patent: January 14, 1986
    Assignee: Research Corporation
    Inventors: Ethan A. Lerner, Michael R. Lerner